Find uplifting stories about heroes, innovations, and solutions
36 results for "daraxonrasib"
A breakthrough drug called daraxonrasib targets the "undruggable" mutation behind 90% of pancreatic cancers, nearly doubling survival time in a major clinical trial. Patients lived 13.2 months compared to 6.7 months with standard chemotherapy.
A new pill called daraxonrasib has doubled survival time for advanced pancreatic cancer patients in a groundbreaking 500-person trial. Oncologists are calling it a grand slam after four decades of failed attempts to crack the disease.
A breakthrough drug called daraxonrasib has doubled survival time for patients with advanced pancreatic cancer, targeting a protein scientists thought was impossible to stop. The FDA has already fast-tracked the treatment, offering new hope for a disease that gives most patients less than a year to live.
A breakthrough drug called daraxonrasib is giving hope to pancreatic cancer patients after scientists spent nearly 50 years trying to target the KRAS mutation. Patients like 36-year-old Leanna Stokes are living far longer than expected thanks to this medical breakthrough.
A breakthrough drug for pancreatic cancer has stunned researchers by controlling disease in 90% of patients who had already tried chemotherapy. The daily pill targets gene mutations found in nearly all pancreatic cancers, offering hope where treatment options have been scarce.
A breakthrough pill is helping pancreatic cancer patients live three to four times longer than with chemotherapy alone. Vicky Stinson, given months to live in 2024, is now thriving two years later thanks to the new treatment.
A breakthrough drug called daraxonrasib doubled survival time for pancreatic cancer patients compared to chemotherapy, offering new hope for one of the deadliest cancers. The treatment targets the genetic mutation behind 90% of pancreatic cancers and causes far fewer severe side effects.
An experimental pill called daraxonrasib helped pancreatic cancer patients live nearly twice as long as those on standard chemotherapy. The breakthrough results, presented at a major cancer conference, mark a historic first for one of medicine's toughest cancers.
An experimental pancreatic cancer treatment that helped patients live nearly twice as long as standard chemotherapy is now reaching patients before formal FDA approval. Revolution Medicines began shipping daraxonrasib to physicians this week through a special early access program.
A breakthrough drug from Revolution Medicines is giving real hope to pancreatic cancer patients for the first time in decades. The pill, called daraxonrasib, successfully targeted KRAS, a protein scientists once thought was impossible to drug.
A new treatment called daraxonrasib has shown remarkable results for advanced pancreatic cancer patients, nearly doubling their survival time in clinical trials. The breakthrough offers fresh hope for one of the deadliest forms of cancer.
A daily pill called daraxonrasib helped control cancer in 90% of pancreatic cancer patients during early trials, offering new hope for a disease that has had few effective treatments. The drug targets genetic mutations found in over 90% of pancreatic cancers.
A breakthrough drug called daraxonrasib has shown it can extend survival in pancreatic cancer patients, one of medicine's toughest challenges. The announcement from Revolution Medicines marks what experts are calling a new era in treating this devastating disease.
Former Senator Ben Sasse was given months to live after a stage 4 pancreatic cancer diagnosis, but an experimental pill has shrunk his tumors by 76% and nearly eliminated his pain. The breakthrough drug could double survival time for patients with this deadly disease.
A revolutionary drug just doubled survival time for patients with advanced pancreatic cancer, one of the deadliest forms of the disease. Doctors are calling it unprecedented, and the breakthrough could soon help patients with lung, colorectal, and other cancers too.
After 40 years without progress, researchers have developed drugs that are doubling survival times for pancreatic cancer patients. One experimental treatment helped half of patients live beyond 13 months, compared to just over six months with standard chemotherapy. ##
A new pill for pancreatic cancer helped patients live nearly twice as long as standard chemotherapy in a groundbreaking study. The experimental drug could bring hope to one of the deadliest cancers within months.
A breakthrough drug that targets the genetic mutation driving 90% of pancreatic cancers has been authorized for expanded access by the FDA. Patients are seeing their cancer stabilized for months longer than expected, with some feeling better within days.
A new pill targeting the KRAS mutation doubles survival time in pancreatic cancer patients, marking the biggest treatment breakthrough ever for one of the world's deadliest cancers. After 25 years of research and $17 million in funding, scientists are finally seeing progress on multiple fronts at once.
A groundbreaking new drug nearly doubled survival time for people with advanced pancreatic cancer, marking the biggest treatment advance in over a decade. The success is sparking hope that other hard-to-treat cancers could soon follow.
Showing 20 of 36